Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

32.85
-0.8500-2.52%
Post-market: 32.850.00000.00%17:10 EDT
Volume:500.65K
Turnover:16.51M
Market Cap:1.94B
PE:-282.55
High:34.54
Open:33.79
Low:32.36
Close:33.70
52wk High:40.22
52wk Low:5.35
Shares:59.15M
Float Shares:43.94M
Volume Ratio:0.34
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1163
EPS(LYR):-0.1163
ROE:-2.37%
ROA:-3.73%
PB:5.51
PE(LYR):-282.55

Loading ...

Stoke Therapeutics Director Adrian R. Krainer Disposes of Common Shares

Reuters
·
Mar 05

Stoke Therapeutics approves $697,125 discretionary bonus for CEO Ian F. Smith

Reuters
·
Mar 04

Stoke Therapeutics CEO Ian F. Smith to Present at TD Cowen 46th Annual Health Care Conference

Reuters
·
Feb 25

Stoke Therapeutics Grants Inducement Stock Options to New Employees

Reuters
·
Feb 19

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 19

High Growth Tech Stocks In The US February 2026

Simply Wall St.
·
Feb 12

Stoke Therapeutics Initiates Early-Stage Study for Genetic Vision Loss Treatment

MT Newswires Live
·
Feb 11

BRIEF-Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002

Reuters
·
Feb 11

Stoke Therapeutics Doses First Patient in Phase 1 Trial of STK-002 for Autosomal Dominant Optic Atrophy

Reuters
·
Feb 11

Stoke Therapeutics Inc: Dose Escalation of First Four Cohorts Will Continue Through 2026 and Early 2027, Pending Safety and Tolerability Assessments

THOMSON REUTERS
·
Feb 11

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of Stk-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (Adoa)

THOMSON REUTERS
·
Feb 11

Stoke Therapeutics präsentiert auf dem Guggenheim Emerging Outlook: Biotech Summit

Reuters
·
Feb 05

Will Stoke’s New Waltham Headquarters for Zorevunersen Commercialization Shift Stoke Therapeutics' (STOK) Narrative?

Simply Wall St.
·
Feb 02

Stoke Therapeutics Signs Lease for New 98,500-Square-Foot Headquarters in Waltham

Reuters
·
Jan 28

How Accelerated EMPEROR Enrollment and Expedited FDA Talks At Stoke Therapeutics (STOK) Have Changed Its Investment Story

Simply Wall St.
·
Jan 25

Stoke Therapeutics (STOK) Valuation Check As Phase 3 Dravet Study Advances And FDA Discussions Progress

Simply Wall St.
·
Jan 22

Stoke Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Jan 17

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 17

Stoke Therapeutics Down Over 16%, on Pace for Largest Percent Decrease Since February 2024 -- Data Talk

Dow Jones
·
Jan 13

Stoke Therapeutics to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 13